TheReal123Trader Posted - 6 hours ago

$JNJ 100% L!ve & Free shared on X. Join The Club till 1-1-2025 for FREE. (testing) - Bought 5/9: 164.99 - Bought 6/9: 164.44 - Sold 10/9: 167.40 +2.68 / +1,63%

gabescorner1995 Posted - 7 hours ago

$JNJ Analysis📊⬇️ Reason for entry: Big bearish pinbar at daily supply and 1hr supply Potential to run: Daily swing at 164.11. Next is a one hour demand at 162.31 Exit with loss: Price breaks and hold above the daily supply I send all my high-quality trades to my free discord

clan Posted - 7 hours ago

$MNKD will be moving up steadily over the next 2+ years. Inhale your mealtime insulin. #Afrezza $JNJ $PFE $GME

Trader_Ty Posted - 8 hours ago

$JNJ 9 is catching up

EthanTrendX Posted - 9 hours ago

$ISRG $JNJ $MDT $WORK

TuG7 Posted - 12 hours ago

$JNJ how come this never goes up in pre mkt regardless of positive news or headlines ??

DonCorleone77 Posted - 12 hours ago

$JNJ Johnson & Johnson announces interim data from SunRISe-4 study Johnson & Johnson announced interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab, or CET, achieved nearly double the pathological complete response, or pCR, rate compared to CET alone in patients with muscle-invasive bladder cancer, or MIBC, who are ineligible or refuse neoadjuvant platinum-based chemotherapy and scheduled for radical cystectomy, or RC. These data were featured as a late-breaking oral presentation at the European Society of Medical Oncology. In the interim analysis of the SunRISe-4 study, neoadjuvant TAR-200 plus CET showed overall efficacy with a centrally confirmed pathologic complete response with CET alone in patients with histologically proven, non-metastatic MIBC. The pathological overall response rate was 60 percent compared to 36 percent, respectively. In a subgroup analysis of patients with organ-confined disease, or cT2, those treated with TAR-200 plus CET showed a 48% pCR rate compared to 23 percent pCR with CET alone and 68% were downstaged at the time of radical cystectomy, potentially improving surgical outcomes and reducing risk of recurrence. Treatment-related adverse events, or TRAEs, occurred in 72% of patients treated with TAR-200 combined with CET and 44% of patients treated with CET alone, with the majority being Grade 1-2. Nine percent of patients discontinued treatment with TAR-200 and eight percent discontinued treatment with CET in the combined treatment cohort due to TRAEs; no patients discontinued treatment due to TRAEs when treated with CET alone.

Stock_Titan Posted - 15 hours ago

$JNJ Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer https://www.stocktitan.net/news/JNJ/neoadjuvant-tar-200-plus-cetrelimab-nearly-doubles-the-pathological-ndvwywrwyyir.html

DonCorleone77 Posted - 1 day ago

$JNJ J&J announces additional results from pivotal Phase 2b SunRISe-1 study Johnson & Johnson announced additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer. New data were featured in a late-breaking oral presentation at the European Society of Medical Oncology 2024 Congress. Pivotal Cohort 2: New results from all 85 patients enrolled in the pivotal cohort show a high, centrally-confirmed, single-agent complete response rate of 83.5%. Results show highly durable CRs without the need for reinduction, with 82% of patients maintaining response after a median follow-up of 9 months, and an estimated 12-month CR rate of 57.4 percent based on the Kaplan-Meier curve. The overall risk-benefit profile favors TAR-200 monotherapy in this patient population. Earlier results from Cohort 2 were previously presented at the 2024 American Urological Association Annual Meeting. Cohorts 1 and 3: First results from Cohort 1 showed a 67.9% centrally-confirmed CR. The first results from Cohort 3 showed a 46.4% centrally-confirmed CR. The overall risk-benefit profile favors TAR-200 monotherapy in this patient population. The CET monotherapy CR rate is numerically similar to previously published CR rates from this class of therapies. Low discontinuation rates due to treatment-resistant adverse events were seen with TAR-200 and CET alone, with higher rates in the combination. The most common TRAEs of any grade across Cohort 1 and 2 were pollakiuria, dysuria, hematuria and urinary tract infection. No treatment-related deaths were reported.

DonCorleone77 Posted - 1 day ago

$JNJ Johnson & Johnson announces new data from Phase 1b/2 OrigAMI-1 study Johnson & Johnson announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT combined with chemotherapy demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer who have not previously received anti-epidermal growth factor receptor therapy. These data were presented in a mini-oral presentation at the European Society of Medical Oncology 2024 Congress. In the study, patients receiving RYBREVANT plus chemotherapy were either in their first or second line of treatment for mCRC and had not been treated with specific anti-EGFR therapies. Patients receiving FOLFOX were oxaliplatin-naive and patients receiving FOLFIRI were irinotecan-naive. Response was assessed by the investigator per RECIST v1.1. Forty-three patients were treated with RYBREVANT along with either FOLFOX or FOLFIRI. The median follow-up period was 7.3 months for RYBREVANT plus FOLFOX and RYBREVANT plus FOLFIRI. Patients treated with RYBREVANT plus chemotherapy achieved an overall response rate of 49 percent, median duration of response of 7.4 months and median progression-free survival of 7.5 months. Disease control was observed in 88 percent of patients. Clinically meaningful intrahepatic antitumor activity was observed among patients with liver metastases treated with RYBREVANT plus chemotherapy, demonstrating a significant reduction in liver tumors. Notably, nine patients were able to proceed to curative-intent surgery due to strong antitumor activity. The safety profile of RYBREVANT plus FOLFOX/FOLFIRI was manageable and consistent with each of the individual components, without any additive toxicity. No new safety signals were observed. The most frequent treatment-emergent adverse events were neutropenia, rash, stomatitis, infusion-related reactions and diarrhea. All IRRs were Grade 1 or 2 and there were no Grade 3 or higher IRR events reported. Treatment-related discontinuations of RYBREVANT were 10% for RYBREVANT plus FOLFOX and nine percent for RYBREVANT plus FOLFIRI. Pivotal Phase 3 registration trials evaluating RYBREVANT-based regimens as first- and second-line treatment in colorectal cancer are planned.

DonCorleone77 Posted - 1 day ago

$JNJ J&J announces updated results from Phase 3 MARIPOSA-2 study Johnson & Johnson announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVAN combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. The data also reveal a favorable trend toward improved overall survival compared to chemotherapy alone. Results were presented at the European Society of Medical Oncology 2024 Congress. At the second interim analysis, with a median follow-up of 18.1 months, 50 percent of patients treated with RYBREVANT plus chemotherapy were still alive at the 18-month landmark, compared to 40 percent of those receiving chemotherapy alone. RYBREVANT plus chemotherapy showed a significant improvement in treatment discontinuation rates, with nearly five times as many patients remaining on therapy at 18 months compared to chemotherapy. Additionally, patients treated with RYBREVANT plus chemotherapy experienced a 27 percent reduction in the risk of symptomatic progression. The time to subsequent therapy was significantly prolonged with the RYBREVANT combination compared to chemotherapy, which also reduced the risk of second disease progression or death by 36 percent. In the MARIPOSA-2 study, the safety profile of RYBREVANT in combination with chemotherapy was consistent with the established profiles of the individual treatments. Permanent discontinuation of RYBREVANT due to adverse reactions occurred in 11 percent of patients. RYBREVANT(R) plus chemotherapy received approval by the European Commision in August 2024 as a treatment for patients with previously treated NSCLC with common EGFR mutations based on the superior efficacy and safety profile demonstrated in this study.

Stock_Titan Posted - 1 day ago

$JNJ New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer https://www.stocktitan.net/news/JNJ/new-data-from-tar-200-phase-2b-sun-ri-se-1-study-show-84-percent-jetbj2ujz3bj.html

KenFaulkenberry Posted - 1 day ago

What is the Intrinsic Value of Johnson & Johnson (JNJ)? $JNJ Intrinsic Value Analysis (Dividend King) https://dividendvaluebuilder.com/johnson-johnson-jnj-stock-analysis/

BartGruen Posted - 2 days ago

$DIA $JNJ $PFE $SCHD $SPY

Stock_Titan Posted - 2 days ago

$JNJ RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer https://www.stocktitan.net/news/JNJ/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-curzgtvhhlm8.html

Ric_1M Posted - 2 days ago

$NFLX $WMT $KO $PEP $JNJ “Your words control your life, your progress, your results, even your mental and physical health. You cannot talk like a failure and expect to be successful.” Germany Kent

GemsBot Posted - 2 days ago

6 of 11 $INTC $JNJ $JPM The best reward to risk ratio trades are when consecutive bars show dark colored signals … see 7/11

cielo1 Posted - 2 days ago

$MRNA $BNTX $PFE $JNJ Please stop all the mRNA products now! The risks are extensive and must be fully understood! https://thehopeaccord.org/ Please help by signing the petition and make it go viral! https://www.youtube.com/live/O7lrzReCOw8?feature=shared

GSMITH10107 Posted - 3 days ago

$OM “60% of future deals are above 1mil each and some are considerably more.” 1.32 and cash per share 3.74 also was in discussion for top 5 best medical device sales in 2024 to buy along with $ABT $INMD $ISRG $JNJ VERY intriguing for a 25 million market cap...... no joke imo https://www.fool.com/investing/stock-market/market-sectors/healthcare/medical-device-stocks/#:~:text=devices%20marketed%20today.-,The%20best%20medical%20device%20stocks%20in%202024,Medical%20(OM%202.31%25).

BartGruen Posted - 3 days ago

$JNJ $SCHD $PFE $DIA #DowJones $SPY #Fed https://seekingalpha.com/article/4720963-johnson-and-johnson-a-strategic-medtech-shift-for-this-dividend-king

LieutenantJoe Posted - 3 days ago

$ELTP this FOMO looks like it will get us into the .75 range at this rate. I think a buyout offer will come sooner than we all think. $LLY $JNJ $PFE watch Eli Lilly, Johnson and Johnson and Pfizer carefully

Stocksrunner Posted - 3 days ago

Unusual Options Activity: $JNJ shows mixed sentiment with balanced puts and calls, signaling potential volatility. $RDFN sees a bullish surge, hinting at a possible rebound. $ALB leans bullish on lithium prospects, while $XOM and $GME remain divided. https://stocksrunner.com/posts/1138

UncleStock Posted - 3 days ago

$RPRX $JNJ $ZTS $MRK suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

NonDucorDuco Posted - 4 days ago

$JNJ Allarity Therapeutics Inc. $ ALLR Ovarian Cancer Drug Treatment .. .. Looking like a B/O Heads Ups .. Big Boy Tutes buying in .. Buying from Institutions increased 36% + in the last 72 hours! That's the data we pay for .. right there!! Fact. Check it out for yourself on Level 2 Data .. I've been in this baby for months .. now it's happening! Enough said .. Just saying .. >>

gabescorner1995 Posted - 4 days ago

$JNJ runner now at 86%. I sent this high-quality trade to my free discord

stockswatcher24 Posted - 4 days ago

$JNJ is a powerhouse in healthcare, and with its focus on innovative treatments, it’s set to remain a top choice for long-term investors.

Market_Manic Posted - 4 days ago

$MRNA stocked getting JABBED! damn $pfe $azn $jnj

basscat12 Posted - 4 days ago

$JNJ $PLTR $VNOM Morning Mash-Up, page 4 and 5, courtesy @TheTradeXchange "Built for Traders, By Traders" and presented with @Vegas1 to help prepare for today's opportunities.

Stock_Titan Posted - 5 days ago

$JNJ TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease https://www.stocktitan.net/news/JNJ/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-8y7ia20hb0gv.html

Aporia Posted - 5 days ago

$JNJ o yeah just resting right there